Page 1

Clinical Update : Micro - dystrophin Gene Therapy Study SRP - 9001-103 : 12 - Week Expression and Safety Data Using Commercially Representative Material DOUG INGRAM President and CEO May 18 , 2021 8:30 a.m. ET & SAREPTA THERAPEUTICS LOUISE RODINO - KLAPAC , PH.D. Executive Vice President and Chief Scientific Officer OSAREPTA THERAPEUTICS , INC . 2021. ALL RIGHTS RESERVED . 1